Chardan Capital Markets downgraded Amicus Therapeutics (NASDAQ: FOLD) from Buy to Neutral saying they see less upside with shares outperforming ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE